Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vivekanand Neginhal

Orthopaedic Surgery Glasgow, KY Medical Doctor

NPI 1578635074 CMS profile 253674

106 Columns Plaza Dr, Glasgow, KY 42141

Open in the dashboard

General payments

$156,327

239 records reported · program years 2019–2025

Research payments

$85,643

Paid to them · 42 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$29,093 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Vivekanand Neginhal of Glasgow, KY is reported in the CMS Open Payments database as having received $156,327 across 239 general payments and $85,643 in research payments paid to them. Separately, studies naming them as principal investigator received $29,093 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $27,037 15
2024 General $13,392 23
2023 General $20,835 33
2022 General $30,476 35
2022 Research $2,525 5
2021 General $11,399 37
2021 Research $11,089 10
2020 General $30,564 27
2020 Research $34,497 13
2019 General $22,624 69
2019 Research $37,532 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vivekanand Neginhal
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Vivekanand Neginhal were reported at $27,037. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Vivekanand Neginhal Orthopaedic Surgery median Middle half National median
2019 $22,624 $644 $140–$2,844 $163
2020 $30,564 $312 $75–$1,860 $114
2021 $11,399 $520 $117–$2,495 $132
2022 $30,476 $598 $128–$2,731 $149
2023 $20,835 $461 $128–$2,264 $160
2024 $13,392 $497 $134–$2,475 $164
2025 $27,037 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Conformis, Inc. $68,214 37 payments
  2. restor3d, inc. $36,862 8 payments
  3. Smith+Nephew, Inc. $32,713 33 payments
  4. Zimmer Biomet Holdings, Inc. $13,093 59 payments
  5. Encore Medical, LP $2,533 13 payments
  6. Stryker Corporation $790 8 payments
  7. Ferring Pharmaceuticals Inc. $428 29 payments
  8. Bioventus LLC $189 9 payments
  9. OMNIlife science, Inc $173 1 payment
  10. Lilly USA, LLC $118 1 payment
  11. Other $1,215 41 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $81,488 19 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $30,080 12 payments
  3. Royalty or License $24,746 4 payments
  4. Travel and Lodging $9,688 29 payments
  5. Food and Beverage $8,859 172 payments
  6. Education $1,465 3 payments
Products named General payments · program years 2019–2025
  1. NAVIO $21,840 7 payments
  2. iTotal Identity PS Orthopedic implants $21,827 2 payments
  3. iTotal Identity CR Knee Replacement System (with CS Insert) Orthopaedic Implants $21,827 2 payments
  4. iTotal Hip $14,790 5 payments
  5. iTotal Identity Cruciate Retaining Knee Replacement System $12,393 2 payments
  6. iTotal Identity PS Orthopaedic Implants $9,771 4 payments
  7. ROSA $7,609 19 payments
  8. iTotal Identity PS Orthopaedic Implants $6,531 4 payments
  9. Journey II XR $6,316 4 payments
  10. iTotal Identity CR Knee Replacement System (with CS Insert) Orthopedic implants $6,181 1 payment
  11. Other $25,056 216 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Conformis, Inc. $85,643 42 payments

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

183

Median for Orthopedic Surgery: 203

Drug cost

$860

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Meloxicam Generic 156 $506
Diclofenac Sodium Generic 13 $331
Tramadol Hcl Generic 14 $24

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$27,481

Of which drugs: $6,458

Medicare patients

65

Average age 73

Services billed

3,390

41 women, 24 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 40%
Depression 37%
Ischemic heart disease 32%
Chronic kidney disease 31%
Atrial fibrillation 23%
COPD 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose J7321 Office 11 31 $1,808
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 49 311 $221

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Lilly USA, LLC $118
$118 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

281 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record